Enrollment completed in the feasibility phase of the foresee clinical trial with biocept's cnside™ assay to evaluate patients with leptomeningeal metastases

San diego--(business wire)---- $bioc #csf--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (nsclc) who have suspicious or confirmed leptomeningeal metastases (lm) in the feasibility phase of its prospective foresee clinical trial (nct0414123). this trial is evaluating the performance of biocept's proprietary cnside assay in monitoring the response to therapy of lm, a c.
BIOC Ratings Summary
BIOC Quant Ranking